Clinical trialPhase 1Terminated
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
Phase I Pilot Study of Endoscopic Ultrasound Guided RFA in Advanced Pancreatic Cancer
- Outcome
- Stopped earlyHalted prematurely (Other)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- 31 March 2023
- Expected end
- 25 February 2025
- Enrollment
- 6 participants
- Sites
- 1
- Primary outcomes
- Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events (AEs) as Assessed by CTCAE v. 5.0
- Sponsor
- Other
- Results posted
- No
- Last update
- 6 November 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients receiving palliative second or third line therapy for unresectable non-metastatic pancreatic cancer.